Drug testing revealed that bleomycin and sirolimus effectively inhibited CD31-positive noninvoluting congenital hemangioma endothelial cells proliferation, with combination therapy showing significant tumor regression in vivo. Here, PECAM1 is linked to congenital hemangioma.